Company Description
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging.
The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.
It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications.
The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015.
Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
| Country | United States |
| IPO Date | May 3, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Dr. Anirvan Ghosh Ph.D. |
Contact Details
Address: 285 East Grand Avenue South San Francisco, California United States | |
| Website | https://unitybiotechnology.com |
Stock Details
| Ticker Symbol | UBX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001463361 |
| CUSIP Number | 91381U101 |
| ISIN Number | US91381U2006 |
| Employer ID | 26-4726035 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Anirvan Ghosh Ph.D. | Chief Executive Officer & Director |
| Alexander Hieu Nguyen J.D. | Chief Legal Officer, Head of Operations & Corporate Secretary |
| Lynne Marie Sullivan CPA | Chief Financial Officer & Head of Corporate Development |
| Alicia Tozier M.B.A. | Chief Strategy Officer |
| Daohong Zhou M.D. | Founder |
| Dr. Federico Grossi M.D., Ph.D. | Chief Medical Officer |
| Dr. Jan M. van Deursen | Founder |
| Dr. Nathaniel E. David A.B., Ph.D. | Co-Founder & Executive Director |
| Dr. Przemyslaw Sapieha Ph.D. | Chief Scientist |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 07, 2025 | 4 | Filing |
| Jan 07, 2025 | 3 | Filing |
| Jan 06, 2025 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 06, 2024 | 4 | Filing |
| Nov 06, 2024 | 4 | Filing |
| Nov 06, 2024 | 4 | Filing |
| Nov 04, 2024 | 10-Q | Quarterly Report |
| Nov 04, 2024 | 8-K | Current Report |
| Aug 06, 2024 | 4 | Filing |